Positive CHMP opinion for glaucoma drops
June 13th 2014The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for brinzolamide 10 mg/mL and brimonidine tartrate 2 mg/mL eye drops suspension (Simbrinza, Alcon) to decrease elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension, for whom monotherapy provides insufficient IOP reduction.
Once daily solution achieves zero-to-trace cell severity
June 11th 2014Bromfenac ophthalmic solution 0.07% (Pro-Lensa, Bausch + Lomb) used once a day results in zero-to-trace (0–5 cells) cell severity in the anterior chamber following cataract surgery with implantation of a posterior chamber IOL, according to newly published research.
Combined treatment for BRVO reduces re-injection need
June 5th 2014Patients who have macular oedema secondary to branch retinal vein occlusion (BRVO) see improved anatomic and functional outcomes with combined intravitreal bevacizumab (IVB) and intravitreal triamcinolone acetate (IVT) therapy when it is delivered early in the disease process, according to the findings of recently published research.
Stents as effective as two medications in OAG
June 4th 2014Implantation of two trabecular micro-bypass devices (iStent inject, Glaukos) reduced intraocular pressure (IOP) at least as effectively as a fixed combination of latanoprost/timolol in patients who had open-angle glaucoma that was not controlled by one medication, according to a recent study.
Refractive outcome shifts toward myopia after combined surgery
May 30th 2014Postoperative refractive outcome shifts toward myopia in patients being treated for rhegmatogenous retinal detachment (RRD) with the combination of phacoemulsification and pars plana vitrectomy, compared with patients who underwent combined surgery for other vitreoretinal pathologies
Dose-ranging study initiated for glaucoma candidate
May 23rd 2014A Phase II dose-ranging study has been initiated for Amakem Therapeutics? glaucoma drug candidate AMA0076, a highly potent, locally acting Rho Kinase (ROCK) inhibitor designed to reduce intraocular pressure (IOP) while minimizing common ROCK inhibitor side effects such as hyperaemia.
Scleral buckling or PPV can treat rhegmatogenous RD in BD
May 22nd 2014Scleral buckling or pars plana vitrectomy (PPV) can be used to treat rhegmatogenous retinal detachment (RD) associated with Beh?et's disease (BD), according to researchers in the Department of Ophthalmology, Zagazig University, Egypt.
Micro-stent is safe and effective after 2-years
May 21st 2014A supracilliary micro-stent, when implanted in conjunction with cataract surgery, substantially reduces intraocular pressure (IOP) with minimal complications in patients with open-angle glaucoma, according to researchers in Germany and the US.
Valve and implant compared for refractory glaucoma
May 16th 2014Patients with refractory glaucoma in whom a proprietary glaucoma implant was placed needed significantly less adjunctive medication to experience success in treatment compared with those who received a proprietary glaucoma valve. However, fewer of those in the latter group had serious postoperative complications, according to recently published 3-year outcomes.
Phase I study data offer hope for NK patients
May 14th 2014Recombinant human Nerve Growth Factor (rhNGF) may offer hope for patients with neurotrophic keratitis (NK), according to researchers in Milan, Italy, who presented preliminary data from a Phase I study at the annual meeting of the Association for Research in Vision and Ophthalmology.
RPE-specific mice suitable for gene activation and inactivation
May 9th 2014A tetracycline-inducible Cre mouse line created specifically to study the retinal pigment epithelium (RPE) is suitable for Cre/lox-based gene activation and inactivation in adult RPE, which makes the mice suitable for long-term studies requiring conditional gene targeting.
Capsular tension ring decreases PCO after surgery
May 8th 2014Implantation of a capsular tension ring effectively reduces the percentage area of posterior capsular opacification (PCO) and the Nd:YAG laser capsulotomy rate in patients with highly myopic eyes, according to researchers in Albania and Turkey.
Meeting preview: Vision UK 2014
May 1st 2014This year, the Vision UK 2014 conference was to be held on Thursday 12 June at the Queen Elizabeth II conference centre in London, UK. Attendees can look forward to key opinion leaders discussing the UK Vision Strategy and emphasizing the initiatives that need to be implemented across the UK.
Multifocal intraocular lens implantation in children
May 1st 2014In children, implantation of a multifocal IOL remains a topic of debate. With lacking evidence on post surgery outcomes and no head-to-head comparison of multifocal IOLs in children, this issue remains to be clarified. Therefore, the authors of this article were prompted to perform research in this area to address a number of concerns among paediatric ophthalmologists.
Neuroprotective effects of cyclosporine A deserve more study
April 25th 2014Cyclosporine A (CSA) protects retinal ganglion cells (RGCs) against glutamate-induced excitotoxicty and should be tested to see whether its neuroprotective properties will work against RGC disorders, researchers recently reported
Topical diclofenac offers no extra benefit for post-PRK pain
April 24th 2014Oral diclofenac sufficiently manages pain after photorefractive keratectomy (PRK), and adding topical diclofenac 0.1% drops to a post-PRK oral diclofenac regimen does not add any additional pain-control benefit, according to recent research.
Endophthalmitis most often caused by Staphylococcus
April 17th 2014Endophthalmitis is most often caused by coagulase-negative Staphylococcus, and the antibiotics vancomycin and ceftazidime seem to perform well in treating it. That was one of the findings of a 25-year retrospective study conducted by Dr Ronald C. Gentile, of the New York Eye and Ear Infirmary, and his colleagues in New York City and San Antonio, Texas, USA.